Research map: Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy

Back to the article

Papers in this map

  1. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ · Richard K. Sterling · 2006 · 5001 citations · Cited by this paper
  2. From HCC Risk Prediction to Surveillance Exemption in Older Adults With MASLD · Rui Li · 2026 · Cites this paper
  3. Comparative Effectiveness and Safety of Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab as First‐Line Systemic Therapy for Hepatocellular Carcinoma: A Real‐World Study · 2026 · Related
  4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3201 citations · Cited by this paper
  5. Antibiotic Resistance Heterogeneity as an Unmeasured Confounder in Tegoprazan–Amoxicillin Dual Therapy Meta‐Analysis · 2026 · Related
  6. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population · Giorgio Bedogni · 2006 · 3178 citations · Cited by this paper
  7. Prospective Clinical Evaluation of a Novel Repositionable Plastic Stent for Endosonography‐Guided Hepaticogastrostomy With or Without Antegrade Stenting (With Videos) · 2026 · Related
  8. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma · Amit G. Singal · 2023 · 1950 citations · Cited by this paper
  9. Response to Interpreting Survival Differences Between Early‐Onset and Later‐Onset Colorectal Cancer: Methodological Considerations · 2026 · Related
  10. Epidemiology of metabolic dysfunction-associated steatotic liver disease · Zobair M. Younossi · 2024 · 876 citations · Cited by this paper
  11. Response to Hassan et al. Regarding the J‐GESS Score · 2026 · Related
  12. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer · Daniel Q. Huang · 2022 · 539 citations · Cited by this paper
  13. Methodological Considerations in Interpreting IL‐15 Plus Thymosin α1 Therapy for Hepatocellular Carcinoma · 2026 · Related
  14. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review · Rohit Seth Loomba · 2020 · 359 citations · Cited by this paper
  15. Navigating liver cancer with mouse models: a comprehensive overview of HCC experimental systems · 2025 · Related
  16. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease · Zobair M. Younossi · 2024 · 312 citations · Cited by this paper
  17. Metabolic Dysfunction–Associated Steatotic Liver Disease · Giovanni Targher · 2025 · 297 citations · Cited by this paper
  18. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment · Soo Young Hwang · 2024 · 295 citations · Cited by this paper
  19. Chemopreventive strategies in hepatocellular carcinoma · Siddharth Singh · 2013 · 276 citations · Cited by this paper
  20. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD · Beom Kyung Kim · 2022 · 107 citations · Cited by this paper
  21. Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin · Rebecca Wenling Zeng · 2023 · 92 citations · Cited by this paper
  22. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease · Huma Saeed · 2024 · 74 citations · Cited by this paper
  23. Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease · Chao Cui · 2025 · 62 citations · Cited by this paper
  24. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis · Harry G. Crane · 2024 · 59 citations · Cited by this paper
  25. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease · Terry Cheuk‐Fung Yip · 2025 · 58 citations · Cited by this paper
  26. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 · Donghee Kim · 2024 · 52 citations · Cited by this paper
  27. KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 · Won Sohn · 2025 · 46 citations · Cited by this paper
  28. Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives · Mengyao Yan · 2024 · 36 citations · Cited by this paper
  29. Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis · Young Eun Chon · 2024 · 34 citations · Cited by this paper
  30. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease · Masahito Nakano · 2024 · 33 citations · Cited by this paper
  31. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study · Byungyoon Yun · 2024 · 33 citations · Cited by this paper
  32. Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease · Yue Wang · 2024 · 31 citations · Cited by this paper
  33. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment · Hee Yeon Kim · 2025 · 31 citations · Cited by this paper
  34. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease · Hye Won Lee · 2017 · 30 citations · Cited by this paper
  35. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study · Michihiro Iwaki · 2024 · 30 citations · Cited by this paper
  36. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease · Jimmy Che‐To Lai · 2025 · 30 citations · Cited by this paper
  37. Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis · Ji Won Han · 2024 · 28 citations · Cited by this paper
  38. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study · Beom Kyung Kim · 2023 · 24 citations · Cited by this paper
  39. Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank · Tae Seop Lim · 2025 · 23 citations · Cited by this paper

Source: OpenAlex (CC0)